在生理环境中合成和天然聚合物微粒的比较稳定性:对药物输送的影响
Hurriyet Polat1, Merve Cevik Eren1, Mehmet Polat2
1Department of Chemistry, Izmir Institute of Technology, Urla 35433, Izmir, Türkiye.
Pharmaceutics
|November 27, 2025
概括
聚合物微粒在体内面临稳定性问题. 自然聚合物比合成聚合物具有更好的稀释阻力,但蛋白质相互作用仍然是药物输送的挑战.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 药物输送系统 药物输送系统
背景情况:
- 聚合物微粒是对疏水药物的有希望的纳米载体.
- 它们在生理条件下的结构稳定性是临床应用的关键限制.
研究的目的:
- 为了比较评估合成和天然聚合物微粒的稳定性.
- 分析影响细菌完整性的因素在稀释下和在富含蛋白质的环境中.
- 审查加强药物输送的菌根稳定性的策略.
主要方法:
- 合成和天然聚合物微粒稳定性的比较分析.
- 控制微粒完整性的热力学和动力学因素的整合.
- 对分子组成,疏水细分长度和核心外修改的审查.
主要成果:
- 在静脉注射后,合成细胞通常会在临界细胞度以下变得不稳定.
- 自然的聚合物微粒 (例如,奇托,酸盐,氨酸) 显示了对稀释的增强抵抗力.
- 这两种类型在生理环境中仍然容易受到蛋白质诱导的不稳定.
结论:
- 天然聚合物微粒在稀释稳定性方面具有优势,但需要进一步修改蛋白质耐受性.
- 诸如交叉连接和表面功能化等策略是改善循环稳定的关键.
- 对于强大,生物相容,可生物降解的细胞药物递送系统,需要一个平衡的设计方法.
相关概念视频
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
185
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
185
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
481
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
481
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
139
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
139
Bioavailability Enhancement: Drug Solubility Enhancement
204
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
204
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
648
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
648


